Inhibrx Biosciences (INBX) Receivables - Net (2024 - 2025)
Inhibrx Biosciences' (INBX) quarterly Receivables - Net came in at $237000.0 in Q2 2025, up 44.51% year-on-year from $164000.0 in Q2 2024, and up 18.5% on a QoQ basis from $200000.0 in Q4 2024.
Inhibrx Biosciences (INBX) Receivables - Net (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Receivables - Net data on file, last reported at $237000.0 in Q2 2025.
- On a quarterly basis, Receivables - Net rose 44.51% year-over-year to $237000.0 in Q2 2025; TTM through Jun 2025 was $237000.0, a 44.51% increase from a year earlier, with the FY2025 full-year figure at $23000.0, down 88.5% from the prior year.
- Receivables - Net for Q2 2025 stood at $237000.0, up from $200000.0 in the prior quarter.
- Over the last five years, Receivables - Net for INBX reached as high as $672000.0 in Q3 2024 and fell as low as $164000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 237,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 672,000.00 |
| Sep 30, 2024 | 672,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 164,000.00 |